Brevan Howard Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Brevan Howard Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72.7K	Buy	63,750 +37,729	+145%	+$44.9K	﹤0.01%	2004
2026 Q1	$36.2K	Sell	26,021 -210,610	-89%	-$289K	﹤0.01%	2105
2025 Q4	$381K	Buy	236,631 +158,510	+203%	+$332K	﹤0.01%	1244
2025 Q3	$213K	Buy	78,121 +60,973	+356%	+$203K	﹤0.01%	1720
2025 Q2	$62.4K	Buy	+17,148	New	+$47.1K	﹤0.01%	1803
2024 Q2	–	Sell	-81,676	Closed	-$149K	–	1036
2024 Q1	$149K	Buy	+81,676	New	+$131K	﹤0.01%	848

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Brevan Howard Capital Management's AKBA Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Akebia Therapeutics (AKBA) stake by 145% in Q2 2026, buying an estimated $44.9K and bringing the position to 63,750 shares worth $72.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2004.

Brevan Howard Capital Management first reported a position in AKBA in Q1 2024 and has held it in 6 quarters since. The position peaked at $381K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Brevan Howard Capital Management held 63,750 shares of Akebia Therapeutics worth $72.7K as of Q2 2026.
Brevan Howard Capital Management bought 37,729 Akebia Therapeutics shares in Q2 2026, an estimated $44.9K.
Akebia Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #2004 holding.
Brevan Howard Capital Management first reported a position in Akebia Therapeutics in Q1 2024 and has held it in 6 quarters since.
Brevan Howard Capital Management's Akebia Therapeutics position peaked at $381K in Q4 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.